Sanctuary Advisors LLC Cuts Stock Position in Abrdn Life Sciences Investors (NYSE:HQL)

Sanctuary Advisors LLC trimmed its position in shares of Abrdn Life Sciences Investors (NYSE:HQL) by 8.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,180 shares of the company’s stock after selling 1,076 shares during the quarter. Sanctuary Advisors LLC’s holdings in Abrdn Life Sciences Investors were worth $172,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Penserra Capital Management LLC bought a new position in shares of Abrdn Life Sciences Investors during the 3rd quarter worth approximately $11,702,000. Absolute Investment Advisers LLC purchased a new position in Abrdn Life Sciences Investors in the fourth quarter worth $5,242,000. Needham Investment Management LLC grew its holdings in Abrdn Life Sciences Investors by 3.2% in the third quarter. Needham Investment Management LLC now owns 352,719 shares of the company’s stock worth $5,319,000 after purchasing an additional 10,904 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of Abrdn Life Sciences Investors by 7.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 91,398 shares of the company’s stock worth $1,199,000 after purchasing an additional 6,200 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new stake in shares of Abrdn Life Sciences Investors during the 3rd quarter valued at $204,000. 32.21% of the stock is currently owned by institutional investors.

Abrdn Life Sciences Investors Price Performance

Abrdn Life Sciences Investors stock opened at $13.28 on Thursday. Abrdn Life Sciences Investors has a 1-year low of $12.76 and a 1-year high of $15.90. The business has a fifty day moving average price of $13.71 and a 200-day moving average price of $14.38.

Abrdn Life Sciences Investors Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Friday, February 21st will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 14.15%. The ex-dividend date of this dividend is Friday, February 21st.

Insider Transactions at Abrdn Life Sciences Investors

In other Abrdn Life Sciences Investors news, major shareholder Saba Capital Management, L.P. sold 15,143 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $14.27, for a total value of $216,090.61. Following the completion of the transaction, the insider now owns 3,381,371 shares of the company’s stock, valued at approximately $48,252,164.17. This trade represents a 0.45 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 108,386 shares of company stock worth $1,511,590. Insiders own 10.06% of the company’s stock.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.